A strategy for regulatory action when new adverse effects of a licensed product emerge.
about
Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysisPharmacovigilanceMedication errors: problems and recommendations from a consensus meeting.The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactionsPost-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
P2860
A strategy for regulatory action when new adverse effects of a licensed product emerge.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A strategy for regulatory action when new adverse effects of a licensed product emerge.
@en
A strategy for regulatory action when new adverse effects of a licensed product emerge.
@nl
type
label
A strategy for regulatory action when new adverse effects of a licensed product emerge.
@en
A strategy for regulatory action when new adverse effects of a licensed product emerge.
@nl
prefLabel
A strategy for regulatory action when new adverse effects of a licensed product emerge.
@en
A strategy for regulatory action when new adverse effects of a licensed product emerge.
@nl
P1433
P1476
A strategy for regulatory action when new adverse effects of a licensed product emerge
@en
P2093
Deirdre Price
P356
10.2165/00002018-200932020-00002
P577
2009-01-01T00:00:00Z
P6179
1003699019